Synthesis and Evaluation of Narrow-Spectrum Antibiotics Targeting MRSA
针对MRSA的窄谱抗生素的合成与评价
基本信息
- 批准号:9981542
- 负责人:
- 金额:$ 14.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAlkynesAmericanAminoglycosidesAnabolismAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsBacterial Antibiotic ResistanceBacterial InfectionsBiochemicalBiochemistryBiologicalBiological AssayCell WallCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChemicalsChemistryClinicalColistinComplexCoupledCrystallizationDataDevelopmentEscherichia coliEvaluationGenesGenomic approachGoalsHumanLabelLibrariesLightMacrolidesMedicineMetabolicMethodologyMethodsMinimum Inhibitory Concentration measurementModificationMolecular BiologyNatural ProductsOrganismPatientsPeptidoglycanPharmacologic SubstancePharmacopoeiasPropertyProteomicsReportingResistanceResistance developmentResortRiskRoentgen RaysSeptic ShockStaphylococcus aureusStructureStructure-Activity RelationshipSuperbugTestingTetracyclinesVancomycinVancomycin-resistant S. aureusactivity-based protein profilingadductanalogbacterial resistancebasebeta-Lactamscomputational chemistrycytotoxicitydesignfallsgenome sequencingglobal healthimprovedinhibitor/antagonistlead candidatemethicillin resistant Staphylococcus aureusmolecular modelingmutantnovelnovel therapeuticspathogenic bacteriaresistance frequencyresponsescaffoldseptic patientstoolwhole genome
项目摘要
Project Summary/Abstract
Natural products account for two-thirds of the antibacterial pharmacopeia and are therefore privileged
scaffolds. These complex molecules have inspired novel synthetic methods and positively impacted the fields
of biochemistry, molecular biology, and medicine. The proposed project is inspired by albocycline, a
unique 14-membered macrolactone with potent, narrow-spectrum activity against the “superbug” methicillin-
resistant Staphylococcus aureus (MRSA). We have validated that albocycline is effective against MRSA and
vancomycin-resistant S. aureus strains; moreover, it is non-toxic to human cells.
In 2013, Tomoda reported that albocycline inhibited peptidoglycan (i.e., bacterial cell wall) synthesis in
macromolecular assays. Using biochemical assays and molecular modeling, we demonstrated that albocycline
was a weak (mM) inhibitor of MurA from S. aureus. Consistent with its narrow-spectrum profile, albocycline did
not inhibit MurA from E. coli. Based on our results and those of Tomoda, we conclude it must have additional
bacterial targets. Significantly, we recently completed a modular, step-efficient total synthesis of the natural
product driven by novel chemistry of N-sulfinyl metallodienamines. Accordingly, in Aim 1 we propose to
prepare albocycline analogs (including probes) by semi- and diverted total synthesis to explore the chemical
space about this privileged scaffold. In Aim 2, we will co-crystallize albocycline in complex with MurA based on
exciting preliminary results and employ structure-based analog design. We will also identify the target(s) of
albocycline to determine its mode-of-action using computational chemistry, chemical proteomics and genomics
approaches, in addition to a novel metabolic labeling methodology. Finally, in Aim 3 we will evaluate the
biological activity of all albocycline analogs.
At the end of the four-year project period, we will have (1) a deeper understanding of how albocycline
exerts its antibacterial action; (2) a library of tool compounds and antibiotic lead candidates that selectively
modulate their target(s); and most significantly, (3) a bona fide launching point for the development of novel,
narrow-spectrum antibiotics to treat recalcitrant MRSA, VISA, and VRSA (i.e., the project's long-term goal).
项目总结/摘要
天然产品占抗菌药物药典的三分之二,因此享有特权
脚手架这些复杂的分子激发了新的合成方法,并对这些领域产生了积极的影响。
生物化学、分子生物学和医学。该拟议项目的灵感来自白环素,一种
独特的14元大环内酯,对“超级细菌”甲氧西林具有强效、窄谱活性,
耐药金黄色葡萄球菌(MRSA)。我们已经验证了albocycline对MRSA有效,
万古霉素抗性S.金黄色葡萄球菌菌株;此外,它对人体细胞无毒。
2013年,Tomoda报道了白霉素抑制肽聚糖(即,细菌细胞壁)合成
大分子测定使用生化测定和分子建模,我们证明白环素
是一个弱的(mM)抑制剂的MurA从S。金黄色。与其窄谱特征一致,
对E.杆菌根据我们的结果和Tomoda的结果,我们得出结论,它必须有额外的
细菌目标。值得注意的是,我们最近完成了一个模块化的,步骤有效的天然全合成,
由N-亚磺酰基金属二烯胺的新化学驱动的产物。因此,在目标1中,我们建议
通过半合成和转向全合成制备albocycline类似物(包括探针),以探索化学
这个特殊的脚手架周围的空间。在目标2中,我们将基于以下共结晶与MurA复合的白环素:
令人兴奋的初步结果,并采用基于结构的模拟设计。我们亦会确定以下的目标:
使用计算化学、化学蛋白质组学和基因组学确定其作用模式
方法,除了一种新的代谢标记方法。最后,在目标3中,我们将评估
所有albocycline类似物的生物活性。
在四年的项目期结束时,我们将有(1)更深入的了解如何albocycline
发挥其抗菌作用;(2)工具化合物和抗生素先导候选物库,
调整他们的目标;最重要的是,(3)小说发展的真正起点,
窄谱抗生素治疗耐药MRSA、VISA和VRSA(即,项目的长期目标)。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and biological evaluation of semi-synthetic albocycline analogs.
- DOI:10.1016/j.bmcl.2020.127509
- 发表时间:2020-11-01
- 期刊:
- 影响因子:2.7
- 作者:Daher SS;Franklin KP;Scherzi T;Dunman PM;Andrade RB
- 通讯作者:Andrade RB
Alternative approaches utilizing click chemistry to develop next-generation analogs of solithromycin.
- DOI:10.1016/j.ejmech.2022.114213
- 发表时间:2022-04-05
- 期刊:
- 影响因子:6.7
- 作者:Daher, Samer S.;Lee, Miseon;Jin, Xiao;Teijaro, Christiana N. N.;Barnett, Pamela R. R.;Freundlich, Joel S. S.;Andrade, Rodrigo B. B.
- 通讯作者:Andrade, Rodrigo B. B.
Staphylococcus aureus resistance to albocycline can be achieved by mutations that alter cellular NAD/PH pools.
- DOI:10.1016/j.bmc.2021.115995
- 发表时间:2021-02-15
- 期刊:
- 影响因子:3.5
- 作者:Scherzi T;D'Ambrosio EA;Daher SS;Grimes CL;Dunman PM;Andrade RB
- 通讯作者:Andrade RB
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RODRIGO B ANDRADE其他文献
RODRIGO B ANDRADE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RODRIGO B ANDRADE', 18)}}的其他基金
Enantioselective Total Synthesis of (+)-Halichlorine
( )-卤氯的对映选择性全合成
- 批准号:
6847444 - 财政年份:2004
- 资助金额:
$ 14.5万 - 项目类别:
Enantioselective Total Synthesis of (+)-Halichlorine
( )-卤氯的对映选择性全合成
- 批准号:
6742018 - 财政年份:2004
- 资助金额:
$ 14.5万 - 项目类别:
相似海外基金
Reactions of Alkynes with Metal-Coordinated Phosphenium Ions
炔烃与金属配位磷离子的反应
- 批准号:
573824-2022 - 财政年份:2022
- 资助金额:
$ 14.5万 - 项目类别:
University Undergraduate Student Research Awards
Exploring the missing reactivity of heteroatom-substituted alkynes
探索杂原子取代的炔烃缺失的反应性
- 批准号:
559671-2021 - 财政年份:2022
- 资助金额:
$ 14.5万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
LEAPS-MPS: Developing a Spectroscopic Map for Terminal Alkynes
LEAPS-MPS:开发末端炔烃的光谱图
- 批准号:
2213339 - 财政年份:2022
- 资助金额:
$ 14.5万 - 项目类别:
Standard Grant
Development of Synthetic Methods for Hetero-fused pi-Conjugated Compounds Based on Trans-Addition to Alkynes
基于炔烃反式加成的异稠合π共轭化合物的合成方法研究进展
- 批准号:
21K05061 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of Enantioselective Carboalumination of Alkenes and Alkynes Catalyzed by Rare-Erath Metal Catalysts
稀土金属催化剂催化烯烃和炔烃对映选择性碳铝化反应的研究进展
- 批准号:
21F21334 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
- 批准号:
10544730 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别:
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
- 批准号:
10320911 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别:
Development of beta-carbon elimination reactions of alkynes from unstrained vinyl complexes
无应变乙烯基配合物中炔烃的β-碳消除反应的进展
- 批准号:
21K05101 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Reactions of Alkynes with Metal-Coordinated Phosphenium Ions
炔烃与金属配位磷离子的反应
- 批准号:
563146-2021 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别:
University Undergraduate Student Research Awards
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
- 批准号:
10581995 - 财政年份:2021
- 资助金额:
$ 14.5万 - 项目类别: